[EN] GLP-1R MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULATEURS DE GLP-1R
申请人:GILEAD SCIENCES INC
公开号:WO2021081207A1
公开(公告)日:2021-04-29
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
[EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL À POTASSIUM DE LA MEDULLA EXTERNE DU REIN
申请人:MERCK SHARP & DOHME
公开号:WO2013039802A1
公开(公告)日:2013-03-21
This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
[EN] HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS<br/>[FR] DÉRIVÉS DE CARBOXAMIDE HÉTÉROAROMATIQUES EN TANT QU'INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2021160718A1
公开(公告)日:2021-08-19
Heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined in the description and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.
[EN] 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] COMPOSÉS DE 4-OXO-3,4-DIHYDROQUINAZOLINE UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
申请人:VIIV HEALTHCARE UK NO 5 LTD
公开号:WO2019198024A1
公开(公告)日:2019-10-17
Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula (I):